MX349054B - Leptinas altamente solubles. - Google Patents
Leptinas altamente solubles.Info
- Publication number
- MX349054B MX349054B MX2013003472A MX2013003472A MX349054B MX 349054 B MX349054 B MX 349054B MX 2013003472 A MX2013003472 A MX 2013003472A MX 2013003472 A MX2013003472 A MX 2013003472A MX 349054 B MX349054 B MX 349054B
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- fatty liver
- chimeric polypeptides
- leptins
- disorders
- Prior art date
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 4
- 208000037765 diseases and disorders Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000000736 Amenorrhea Diseases 0.000 abstract 1
- 206010001928 Amenorrhoea Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 102000016267 Leptin Human genes 0.000 abstract 1
- 108010092277 Leptin Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033307 Overweight Diseases 0.000 abstract 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 abstract 1
- 231100000540 amenorrhea Toxicity 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 230000002267 hypothalamic effect Effects 0.000 abstract 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 1
- 229940039781 leptin Drugs 0.000 abstract 1
- 208000006132 lipodystrophy Diseases 0.000 abstract 1
- 208000011661 metabolic syndrome X Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38740210P | 2010-09-28 | 2010-09-28 | |
| US42209110P | 2010-12-10 | 2010-12-10 | |
| PCT/US2011/053774 WO2012050925A2 (en) | 2010-09-28 | 2011-09-28 | Highly soluble leptins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013003472A MX2013003472A (es) | 2013-10-30 |
| MX349054B true MX349054B (es) | 2017-07-07 |
Family
ID=45938879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013003472A MX349054B (es) | 2010-09-28 | 2011-09-28 | Leptinas altamente solubles. |
| MX2013003482A MX351128B (es) | 2010-09-28 | 2011-09-28 | Polipeptidos manipulados que tienen duracion de accion incrementada. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013003482A MX351128B (es) | 2010-09-28 | 2011-09-28 | Polipeptidos manipulados que tienen duracion de accion incrementada. |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US20130203661A1 (enExample) |
| EP (4) | EP2621519B1 (enExample) |
| JP (5) | JP6174489B2 (enExample) |
| CN (2) | CN103403019B (enExample) |
| BR (3) | BR112013007388B1 (enExample) |
| CA (3) | CA3138758A1 (enExample) |
| CY (2) | CY1119023T1 (enExample) |
| DK (3) | DK3241558T3 (enExample) |
| EA (2) | EA032917B1 (enExample) |
| ES (3) | ES2641869T3 (enExample) |
| MX (2) | MX349054B (enExample) |
| PL (1) | PL3241558T3 (enExample) |
| PT (2) | PT2621519T (enExample) |
| WO (2) | WO2012050925A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012004384A2 (en) | 2010-07-09 | 2012-01-12 | Affibody Ab | Polypeptides |
| PT2621519T (pt) * | 2010-09-28 | 2017-10-04 | Aegerion Pharmaceuticals Inc | Polipéptido de fusão de leptina-abd com duração de ação melhorada |
| CN103957926B (zh) * | 2011-07-08 | 2018-07-03 | 安米林药品有限责任公司 | 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽 |
| HK1208155A1 (en) * | 2012-03-28 | 2016-02-26 | Amylin Pharmaceuticals, Llc | Transmucosal delivery of engineered polypeptides |
| CN104662035A (zh) * | 2012-09-25 | 2015-05-27 | 阿菲博迪公司 | 白蛋白结合多肽 |
| RU2679889C2 (ru) | 2013-04-18 | 2019-02-14 | Армо Байосайенсиз, Инк. | Способы применения интерлейкина-10 для лечения заболеваний и расстройств |
| US9823255B2 (en) | 2013-06-17 | 2017-11-21 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| WO2015031316A1 (en) | 2013-08-30 | 2015-03-05 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| CN105848674A (zh) | 2013-11-11 | 2016-08-10 | 阿尔莫生物科技股份有限公司 | 将白细胞介素-10用于治疗疾病和病症的方法 |
| US10167322B2 (en) | 2013-12-20 | 2019-01-01 | Affibody Ab | Engineered albumin binding polypeptide |
| CN106573072A (zh) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | 降低血清胆固醇的方法 |
| CN106687474A (zh) * | 2014-09-04 | 2017-05-17 | 诺和诺德股份有限公司 | 新型胰淀素和降钙素受体激动剂 |
| WO2016060996A2 (en) | 2014-10-14 | 2016-04-21 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| MX2017004983A (es) | 2014-10-22 | 2017-11-13 | Armo Biosciences Inc | Metodos para usar interleucina 10 para tratar enfermedades y trastornos. |
| WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| JP7121496B2 (ja) | 2015-05-28 | 2022-08-18 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 癌治療で使用するためのペグ化インターロイキン－１０ |
| CN113201048B (zh) | 2015-08-05 | 2022-10-04 | 陕西麦科奥特科技有限公司 | 有抗凝血和抗血小板活性的多靶点化合物及制法和用途 |
| WO2017053391A1 (en) | 2015-09-22 | 2017-03-30 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
| US10286079B2 (en) | 2015-09-22 | 2019-05-14 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
| KR20180059922A (ko) | 2015-10-02 | 2018-06-05 | 유니버시티 오브 코펜하겐 | 히스톤 리더 도메인을 차단하는 소분자 |
| MX2019002818A (es) | 2016-09-12 | 2019-08-29 | Aegerion Pharmaceuticals Inc | Metodos para detectar anticuerpos neutralizantes anti-leptina. |
| MX2019008827A (es) * | 2017-01-30 | 2019-09-26 | Alexion Pharma Inc | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. |
| KR20200143431A (ko) * | 2018-04-13 | 2020-12-23 | 메사추세츠 인스티튜트 오브 테크놀로지 | 모발 복구 및 오래-지속되는 색 유지를 위한 조작된 트리트먼트 |
| EP3711772A1 (en) * | 2019-03-20 | 2020-09-23 | Oslo Universitetssykehus HF | Recombinant proteins and fusion proteins |
| EP4405494A4 (en) * | 2021-09-24 | 2025-12-17 | Uab Res Found | CONTROL OF SUBUNITIOMETRY IN SINGLE-CHAIN MSP NANOPORES |
| WO2025240494A1 (en) * | 2024-05-13 | 2025-11-20 | Lumen Bioscience, Inc. | Leptin compositions and methods of making and using the same to support weight loss and/or maintenance |
Family Cites Families (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US4572208A (en) | 1983-06-29 | 1986-02-25 | Utah Medical Products, Inc. | Metabolic gas monitoring apparatus and method |
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
| FI78231C (fi) | 1984-11-21 | 1989-07-10 | Instrumentarium Oy | Maetanordning foer metaboliska storheter anslutbar till en respirator. |
| US4695463A (en) | 1985-05-24 | 1987-09-22 | Warner-Lambert Company | Delivery system for active ingredients and preparation thereof |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| HU220234B (hu) | 1989-10-16 | 2001-11-28 | Amgen Inc. | Eljárás stem sejtek működését befolyásoló faktorok előállitására |
| US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
| CA2107553C (en) | 1991-04-05 | 2001-07-31 | Nancy Lin | Monoclonal antibodies to stem cell factor receptors |
| NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| US5766627A (en) | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
| US6288030B1 (en) | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6048837A (en) | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
| US5574133A (en) | 1995-01-31 | 1996-11-12 | Eli Lilly And Company | Anti-obesity proteins |
| US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5567803A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
| US5554727A (en) | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
| US5605886A (en) | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
| JPH10513450A (ja) | 1995-01-31 | 1998-12-22 | イーライ・リリー・アンド・カンパニー | 抗肥満症タンパク質 |
| US5563243A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5563245A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5569743A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
| US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5525705A (en) | 1995-01-31 | 1996-06-11 | Eli Lilly And Company | Anti-obesity proteins |
| AU4766596A (en) | 1995-01-31 | 1996-08-21 | Eli Lilly And Company | Ob gene product antibodies |
| US5580954A (en) | 1995-01-31 | 1996-12-03 | Eli Lilly And Company | Anti-obesity proteins |
| JPH11501297A (ja) | 1995-01-31 | 1999-02-02 | イーライ・リリー・アンド・カンパニー | 抗肥満症タンパク質 |
| US5567678A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
| US5563244A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| US5594104A (en) | 1995-01-31 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| US5569744A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
| US5559208A (en) | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
| US5594101A (en) | 1995-03-03 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
| US5719266A (en) | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
| EP0736599A3 (en) | 1995-04-03 | 1996-12-11 | Takeda Chemical Industries Ltd | The rat obesity gene, its gene product and its production |
| WO1996031526A1 (en) | 1995-04-06 | 1996-10-10 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
| US5614379A (en) | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
| US5840517A (en) * | 1995-04-26 | 1998-11-24 | Eli Lilly And Company | Process for preparing obesity protein analogs |
| EP0741187A2 (en) | 1995-05-05 | 1996-11-06 | F. Hoffmann-La Roche Ag | Recombinant obese (Ob) proteins |
| GB9509164D0 (en) | 1995-05-05 | 1995-06-28 | Smithkline Beecham Plc | Novel compounds |
| CA2218529A1 (en) | 1995-05-08 | 1996-11-14 | Chiron Corporation | Nucleic acids for treating obesity |
| EP0744408A3 (en) | 1995-05-26 | 1997-01-02 | Eli Lilly And Company | Rhesus ob protein and DNA |
| CA2223433C (en) | 1995-06-07 | 2003-11-18 | Amgen Inc. | Ob protein compositions and methods |
| US5581005A (en) | 1995-06-16 | 1996-12-03 | The Procter & Gamble Company | Method for manufacturing cobalt catalysts |
| WO1997000886A1 (en) | 1995-06-22 | 1997-01-09 | Eli Lilly And Company | Obesity protein intermediates and their preparation and use |
| GB2302559B (en) | 1995-06-23 | 1998-06-03 | Draftex Ind Ltd | Opening arrangements and methods for closure members |
| CA2224381A1 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| EA199800104A1 (ru) | 1995-06-30 | 1998-10-29 | Эли Лилли Энд Компани | Способ лечения диабета |
| WO1997006816A1 (en) | 1995-08-17 | 1997-02-27 | Amgen Inc. | Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions |
| WO1997016550A1 (en) | 1995-11-02 | 1997-05-09 | Bristol-Myers Squibb Company | Polypeptide fragments derived from the obese gene product |
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| ATE259243T1 (de) | 1995-11-22 | 2004-02-15 | Amgen Inc | Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse |
| WO1997020933A2 (en) | 1995-12-06 | 1997-06-12 | Schering Corporation | MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| US5831017A (en) | 1996-01-25 | 1998-11-03 | Eli Lilly And Company | Obesity protein analog compounds and formulations thereof |
| US6013009A (en) | 1996-03-12 | 2000-01-11 | Karkanen; Kip Michael | Walking/running heart rate monitoring system |
| WO1997038014A1 (en) | 1996-04-04 | 1997-10-16 | Amgen Inc. | Fibulin pharmaceutical compositions and related methods |
| US6025324A (en) | 1996-05-15 | 2000-02-15 | Hoffmann-La Roche Inc. | Pegylated obese (ob) protein compositions |
| CZ397898A3 (cs) | 1996-06-06 | 1999-04-14 | Smithkline Beecham P. L. C. | Fragment leptinu (OB proteinu) |
| US5922678A (en) | 1996-06-28 | 1999-07-13 | Eli Lilly And Company | Methods for treating diabetes |
| WO1998008512A1 (en) | 1996-08-30 | 1998-03-05 | Amgen Inc. | Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor |
| KR20010029537A (ko) | 1996-09-20 | 2001-04-06 | 훽스트 악티엔게젤샤프트 | 제ⅱ형 당뇨병에서의 인슐린 내성을 치료하기 위한 렙틴 길항제의 용도 |
| AU4582597A (en) | 1996-10-11 | 1998-05-11 | Eli Lilly And Company | Therapeutic proteins |
| WO1998024896A2 (en) | 1996-12-06 | 1998-06-11 | F. Hoffmann-La Roche Ag | Muteins of obese protein |
| DK0954588T3 (da) | 1996-12-20 | 2007-05-14 | Amgen Inc | OB fusionsprotein-sammensætninger og fremgangsmåder |
| US6309360B1 (en) | 1997-03-17 | 2001-10-30 | James R. Mault | Respiratory calorimeter |
| AU6569998A (en) * | 1997-03-20 | 1998-10-12 | Eli Lilly And Company | Obesity protein formulations |
| HUP0003428A3 (en) | 1997-06-06 | 2001-12-28 | Smithkline Beecham Plc | Use of leptin antagonists for the treatment of diabetes |
| ES2235336T3 (es) | 1997-06-13 | 2005-07-01 | Gryphon Therapeutics, Inc. | Ligacion quimica nativa en fase solida de peptidos desprotegidos o protegidos en la cisteina n-terminal en solucion acuosa. |
| DE69942453D1 (de) | 1998-05-29 | 2010-07-15 | Jgc Catalysts & Chemicals Ltd | Verfahren zur herstellung photoelektrischer zellen |
| AU5347099A (en) | 1998-08-10 | 2000-03-06 | Amgen, Inc. | Dextran-leptin conjugates, pharmaceutical compositions and related methods |
| AU6396999A (en) | 1998-10-02 | 2000-04-26 | Amgen, Inc. | Method to determine a predisposition to leptin treatment |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| BRPI0007823A8 (pt) | 1999-01-14 | 2017-03-21 | Amylin Pharmaceuticals Inc | Métodos de supressão do glucagon |
| ATE323766T1 (de) | 1999-02-12 | 2006-05-15 | Amgen Inc | Glykosylierte leptinzusammensetzungen und zugehörige verfahren |
| US6475984B2 (en) * | 1999-04-29 | 2002-11-05 | The Nemours Foundation | Administration of leptin |
| TW514510B (en) | 1999-06-11 | 2002-12-21 | Tanita Seisakusho Kk | Method and apparatus for measuring distribution of body fat |
| US6468222B1 (en) | 1999-08-02 | 2002-10-22 | Healthetech, Inc. | Metabolic calorimeter employing respiratory gas analysis |
| US6258932B1 (en) | 1999-08-09 | 2001-07-10 | Tripep Ab | Peptides that block viral infectivity and methods of use thereof |
| CA2388417A1 (en) * | 1999-09-22 | 2001-03-29 | Genset | Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
| US6530886B1 (en) | 1999-10-08 | 2003-03-11 | Tanita Corporation | Method and apparatus for measuring subcutaneous fat using ultrasonic wave |
| US7057015B1 (en) * | 1999-10-20 | 2006-06-06 | The Salk Institute For Biological Studies | Hormone receptor functional dimers and methods of their use |
| CN1423566A (zh) | 1999-11-10 | 2003-06-11 | 武田药品工业株式会社 | 体重增加抑制剂 |
| JP2001199887A (ja) | 1999-11-10 | 2001-07-24 | Takeda Chem Ind Ltd | 体重増加抑制剤 |
| US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US7157564B1 (en) | 2000-04-06 | 2007-01-02 | Affymetrix, Inc. | Tag nucleic acids and probe arrays |
| EP2275557A1 (en) * | 2000-04-12 | 2011-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| TW515705B (en) | 2000-05-31 | 2003-01-01 | Yamato Scale Co Ltd | Visceral fat meter |
| US6492117B1 (en) | 2000-07-12 | 2002-12-10 | Gendaq Limited | Zinc finger polypeptides capable of binding DNA quadruplexes |
| US6296842B1 (en) | 2000-08-10 | 2001-10-02 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
| US6475158B1 (en) | 2000-10-24 | 2002-11-05 | Korr Medical Technologies, Inc. | Calorimetry systems and methods |
| PL214862B1 (pl) | 2001-10-22 | 2013-09-30 | Amgen | Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny |
| US6899892B2 (en) | 2001-12-19 | 2005-05-31 | Regents Of The University Of Minnesota | Methods to reduce body fat |
| EP2990417A1 (en) | 2001-12-21 | 2016-03-02 | Human Genome Sciences, Inc. | Albumin insulin fusion protein |
| WO2004039832A2 (en) | 2002-10-31 | 2004-05-13 | Albany Medical College | Leptin-related peptides |
| KR20050084751A (ko) | 2002-11-01 | 2005-08-29 | 가부시끼가이샤 도꾸야마 | 중합성 조성물, 그의 경화체의 제조법 및 광학 물품 |
| JP4949838B2 (ja) * | 2003-09-19 | 2012-06-13 | ノヴォ ノルディスク アー／エス | 新規ｇｌｐ−１誘導体 |
| WO2005028516A2 (en) * | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| ES2345113T3 (es) | 2004-02-11 | 2010-09-15 | Amylin Pharmaceuticals, Inc. | Peptidos de la familia amilina y metodos para su obtencion y utilizacion. |
| US7399744B2 (en) | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| EP1841796A2 (en) | 2004-12-02 | 2007-10-10 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
| US7898623B2 (en) | 2005-07-04 | 2011-03-01 | Semiconductor Energy Laboratory Co., Ltd. | Display device, electronic device and method of driving display device |
| GB0524788D0 (en) * | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| US20070238669A1 (en) | 2006-01-11 | 2007-10-11 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions |
| EP1996617A2 (en) | 2006-03-15 | 2008-12-03 | Novo Nordisk A/S | Amylin derivatives |
| JP2009538824A (ja) | 2006-03-31 | 2009-11-12 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 精神疾患及び障害治療用アミリン及びアミリンアゴニスト |
| BRPI0712559A2 (pt) | 2006-05-26 | 2012-11-20 | Amylin Pharmaceuticals Inc | composiÇÕes e mÉtodos para o tratamento de insuficiÊncia cardÍaca congestiva |
| WO2007139589A1 (en) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| CN101113175A (zh) * | 2007-04-28 | 2008-01-30 | 中国科学院西北高原生物研究所 | 鼠兔家族瘦素蛋白及其cDNA序列 |
| JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
| US8937153B2 (en) * | 2007-07-31 | 2015-01-20 | Affibody Ab | Compositions, methods and uses |
| GB0715216D0 (en) | 2007-08-03 | 2007-09-12 | Asterion Ltd | Leptin |
| EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| WO2009042922A2 (en) * | 2007-09-27 | 2009-04-02 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
| AU2007360979B2 (en) | 2007-11-14 | 2014-04-10 | Amylin Pharmaceuticals, Llc | Methods for treating obesity and obesity related diseases and disorders |
| MX2010008632A (es) * | 2008-02-08 | 2010-08-30 | Ambrx Inc | Leptina-polipeptidos modificados y sus usos. |
| WO2009149379A2 (en) | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
| CN102197049B (zh) | 2008-10-21 | 2015-03-25 | 诺沃-诺迪斯克有限公司 | 胰岛淀粉样多肽衍生物 |
| WO2010054699A1 (en) * | 2008-11-17 | 2010-05-20 | Affibody Ab | Conjugates of albumin binding domain |
| AU2010206614B2 (en) | 2009-01-22 | 2015-03-26 | Keybioscience Ag | Treatment for obesity |
| PL2393828T3 (pl) | 2009-02-03 | 2017-06-30 | Amunix Operating Inc. | Wydłużone rekombinowane polipeptydy i zawierające je kompozycje |
| ES2676874T3 (es) * | 2010-06-04 | 2018-07-25 | Tiumbio Co., Ltd. | Proteína de fusión que tiene actividad del factor VII |
| WO2012004384A2 (en) | 2010-07-09 | 2012-01-12 | Affibody Ab | Polypeptides |
| PT2621519T (pt) | 2010-09-28 | 2017-10-04 | Aegerion Pharmaceuticals Inc | Polipéptido de fusão de leptina-abd com duração de ação melhorada |
| ES2563091T3 (es) | 2010-09-28 | 2016-03-10 | Amylin Pharmaceuticals, Llc | Polipéptidos modificados genéticamente que tienen duración de acción potenciada |
| JP6006309B2 (ja) | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
| CN103957926B (zh) * | 2011-07-08 | 2018-07-03 | 安米林药品有限责任公司 | 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽 |
-
2011
- 2011-09-28 PT PT118330802T patent/PT2621519T/pt unknown
- 2011-09-28 CN CN201180057153.4A patent/CN103403019B/zh active Active
- 2011-09-28 BR BR112013007388-8A patent/BR112013007388B1/pt active IP Right Grant
- 2011-09-28 WO PCT/US2011/053774 patent/WO2012050925A2/en not_active Ceased
- 2011-09-28 DK DK17163203.7T patent/DK3241558T3/da active
- 2011-09-28 BR BR112013007385-3A patent/BR112013007385B1/pt active IP Right Grant
- 2011-09-28 BR BR122021020041-6A patent/BR122021020041B1/pt active IP Right Grant
- 2011-09-28 EA EA201390497A patent/EA032917B1/ru unknown
- 2011-09-28 ES ES11833080.2T patent/ES2641869T3/es active Active
- 2011-09-28 DK DK11833075.2T patent/DK2621515T3/en active
- 2011-09-28 CN CN201180056939.4A patent/CN103547590B/zh active Active
- 2011-09-28 EP EP11833080.2A patent/EP2621519B1/en active Active
- 2011-09-28 ES ES11833075.2T patent/ES2630031T3/es active Active
- 2011-09-28 CA CA3138758A patent/CA3138758A1/en active Pending
- 2011-09-28 EP EP17163203.7A patent/EP3241558B1/en active Active
- 2011-09-28 CA CA2813087A patent/CA2813087C/en active Active
- 2011-09-28 PL PL17163203T patent/PL3241558T3/pl unknown
- 2011-09-28 JP JP2013531786A patent/JP6174489B2/ja active Active
- 2011-09-28 EA EA201390474A patent/EA024507B1/ru unknown
- 2011-09-28 EP EP11833075.2A patent/EP2621515B1/en active Active
- 2011-09-28 PT PT118330752T patent/PT2621515T/pt unknown
- 2011-09-28 EP EP17174544.1A patent/EP3305315A1/en not_active Withdrawn
- 2011-09-28 WO PCT/US2011/053786 patent/WO2012050930A2/en not_active Ceased
- 2011-09-28 CA CA2813038A patent/CA2813038C/en active Active
- 2011-09-28 DK DK11833080.2T patent/DK2621519T3/en active
- 2011-09-28 JP JP2013531789A patent/JP2014502252A/ja active Pending
- 2011-09-28 MX MX2013003472A patent/MX349054B/es active IP Right Grant
- 2011-09-28 MX MX2013003482A patent/MX351128B/es active IP Right Grant
- 2011-09-28 ES ES17163203T patent/ES2873253T3/es active Active
-
2013
- 2013-03-28 US US13/852,521 patent/US20130203661A1/en not_active Abandoned
- 2013-03-28 US US13/852,671 patent/US20130274182A1/en not_active Abandoned
-
2015
- 2015-05-04 US US14/703,523 patent/US10087228B2/en active Active
- 2015-07-15 US US14/800,537 patent/US20160137709A1/en not_active Abandoned
-
2016
- 2016-12-02 JP JP2016235165A patent/JP6608799B2/ja active Active
-
2017
- 2017-02-28 JP JP2017036849A patent/JP6412183B2/ja active Active
- 2017-06-28 CY CY20171100690T patent/CY1119023T1/el unknown
- 2017-09-26 CY CY20171101013T patent/CY1119498T1/el unknown
-
2019
- 2019-10-24 JP JP2019193539A patent/JP2020033366A/ja active Pending
-
2020
- 2020-01-24 US US16/751,538 patent/US11535659B2/en active Active
-
2022
- 2022-10-25 US US18/049,445 patent/US20230115655A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX349054B (es) | Leptinas altamente solubles. | |
| WO2013009539A8 (en) | Engineered polypeptides having enhanced duration of action and reduced immunogenicity | |
| EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| WO2011082270A3 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| WO2010059241A3 (en) | Treatment of amyotrophic lateral sclerosis | |
| WO2011082267A3 (en) | Substituted triazolo-pyrazine compounds | |
| MX2011013903A (es) | Polipeptidos quimericos y usos de los mismos. | |
| WO2010078421A8 (en) | Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds | |
| JP2017081939A5 (enExample) | ||
| PH12015502433B1 (en) | Fgf21 mutants and uses thereof | |
| MA32771B1 (fr) | Mutants fgf21 et leurs utilisations | |
| WO2007030375A3 (en) | Lysosomal acid lipase therapy for nafld and related diseases | |
| TW200630327A (en) | Substituted phenylalkanoic acids | |
| PH12014500866A1 (en) | Immunobinders directed against tnf | |
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| MX2011013577A (es) | Composiciones y metodos para tratar esclerosis lateral amiotrofica. | |
| MXPA05011524A (es) | Acidos carboxilicos sustituidos. | |
| WO2011002834A3 (en) | Compositions and methods for diagnosis and treatment of type 1 diabetes | |
| WO2011082268A3 (en) | Substituted naphthalenyl-pyrimidine compounds | |
| BRPI0917245A8 (pt) | Compostos derivados de isoquinolinona e sua composição farmacêutica | |
| TW200630354A (en) | Substituted amino carboxylic acids | |
| WO2010129048A3 (en) | Therapeutic compounds | |
| WO2010129665A3 (en) | Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis | |
| MX2019002579A (es) | Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado. | |
| TW200631949A (en) | Substituted carboxylic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: AEGERION PHARMACEUTICALS, INC. |
|
| FG | Grant or registration |